European Primary Care Cardiovascular Society

Treatment of high-risk ACS patients may change based on ODYSSEY OUTCOMES study results

Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA

ACC 2018 Dr. Valentin Fuster explains why he thinks that the results with the PCSK9 inhibitor alirocumab can change clinical practice. In the results he also sees the message that LDL levels now considered normal, may actually be too high.

Educational information

This 3-minute education provides a commentary on just presented scientific data, recorded during the ACC 2018 in Orlando. The objective is to provide a brief commentary and potential implications of these findings.

Faculty

Dr. Valentin Fuster is a cardiologist in New York, NY and is affiliated with multiple hospitals in the area, including Mount Sinai Hospital and NYC Health and Hospitals/Bellevue.

Disclosures

This recording was independently developed under auspices of EPCCS. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of EPCCS.

Read more about the results of the ODYSSEY OUTCOMES trial